Baxter International

Latest Headlines

Latest Headlines

ALSO NOTED: FDA says no to Indevus; Nektar gets sweetened deal with Baxter; Akela pulls public offering; and much more...

> Indevus Pharmaceuticals says that the FDA has turned thumbs down on its new therapy for bladder cancer, a move that trimmed its stock value. Valstar was pulled from the market five years ago

ALSO NOTED: Halozyme inks tech pact; Bioniche gains SPA; Ariad shares on rise; and much more...

> Halozyme Therapeutics has agreed to put its technology to work to develop a new formulation of Baxter's Gammagard Liquid for subcutaneous delivery. Gammagard is used to treat primary

SPOTLIGHT: Baxter bullish on Gammagard

Baxter International says that a preliminary analysis of data from a Phase II study of Gammagard for Alzheimer's has produced enough encouraging signs to lay the groundwork for Phase III. The next